Efficacy of SCH39304 in murine cryptococcosis

Cryptococcal meningitis is increasing in frequency, in large part because of the advent of acquired immune deficiency syndrome. Using the murine cryptococcosis model, a new oral triazole, SCH39304, has been compared with two drugs in clinical use, fluconazole and amphotericin B. BALB/c mice (nu/nu and nu/+) were challenged intracerebrally or intranasally. Oral treatment was given daily with SCH39304 at doses of 1 to 60 mg/kg of body weight or fluconazole at doses of 1 or 5 mg/kg of body weight. Amphotericin B was given intraperitoneally three times weekly, at doses of 3 or 6 mg/kg. After intracerebral challenge, SCH39304 prolonged survival in doses as low as 1 mg/kg, a dose at which fluconazole was ineffective. At equal doses, SCH39304 consistently increased survival more than did fluconazole but not longer than did amphotericin B. SCH39304 significantly lowered colony counts in brains more than did fluconazole but no more than did amphotericin B. SCH39304 was also superior to fluconazole after intranasal challenge at equal doses. SCH39304 appears to be superior to fluconazole in mice when the drugs are given at equal doses. Clinical trials are warranted.

[1]  K. Squires,et al.  Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. , 1988, The American journal of medicine.

[2]  P. Cohen,et al.  Gastric secretory failure in patients with the acquired immunodeficiency syndrome (AIDS). , 1988, Annals of internal medicine.

[3]  W. Byrne,et al.  Cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS): successful treatment with fluconazole after failure of amphotericin B. , 1988, Annals of internal medicine.

[4]  F. Balis,et al.  Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. , 1988, The Journal of infectious diseases.

[5]  R. Diasio,et al.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. , 1987, The New England journal of medicine.

[6]  K. Chapin,et al.  Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts , 1986, Journal of clinical microbiology.

[7]  A. Zuger,et al.  Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. , 1986, Annals of internal medicine.

[8]  E. Gelmann,et al.  Cryptococcosis in the acquired immunodeficiency syndrome. , 1985, Annals of internal medicine.

[9]  R. Hershberger,et al.  Treatment of central nervous system fungal infection with ketoconazole. , 1985, Archives of internal medicine.

[10]  J. Graybill,et al.  R 51211 (itraconazole) therapy of murine cryptococcosis. , 1984, Sabouraudia.

[11]  J. Washington,et al.  Discrepancies between in vitro activity of and in vivo response to antimicrobial agents. , 1983, Diagnostic microbiology and infectious disease.

[12]  J. Perfect,et al.  Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole. , 1982, The Journal of infectious diseases.

[13]  J. Graybill,et al.  Treatment of murine cryptococcosis with liposome-associated amphotericin B. , 1982, The Journal of infectious diseases.

[14]  E. Van Cutsem,et al.  Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole. , 1980, Reviews of infectious diseases.

[15]  D. Alling,et al.  A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. , 1979, The New England journal of medicine.